Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study
Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study
复制标题
DOI：
10.1016/j.schres.2009.03.014
复制
发表时间：
2009-06-01
影响因子：
4.5
通讯作者：
Chen, Jen-Yeu
中科院分区：
文献类型：
--
作者：
Bai, Ya Mei;Chen, Tzu Ting;Chen, Jen-Yeu
简介：脂联素是一种脂肪细胞源性的控制脂质和碳水化合物代谢的激素，已被认为是一般人群中代谢综合征的生物标志物。本研究探讨脂联素水平和代谢综合征的患者治疗与非典型antipsychotic.Methods：人体测量和代谢参数和血清脂联素水平进行了评估，在住院的精神分裂症患者谁使用了相同的非典型抗精神病药至少3个月。对患者的病历进行回顾性分析，以获得人口统计学数据和治疗前的特征。结果：该研究包括567例精神分裂症患者治疗氯氮平（n = 231）奥氮平（n = 94）和利培酮（n = 242），平均45.8 +/- 27.8个月。所有受试者中代谢综合征的患病率为23.8%。氯氮平组代谢综合征患病率较高（28.7%）比奥氮平利培酮组为24.2%，（19.5%）（P=0.039），氯氮平组脂联素水平较低（8.46 ± 6.02 mg/mL）高于奥氮平组（10.26 ± 4.9 mg/mL）和利培酮组（10.69 ± 7.43 mg/mL）（P=0.001）。脂联素水平与开始抗精神病药物治疗后体重指数（BMI）增加呈负相关。横断面回归分析显示年龄（OR = 1.042，P=0.001）、BMI（OR=1.404，P
introduction: Adiponectin, an adipocyte-derived hormone controlling lipid and carbohydrate metabolism, has been suggested to be a biomarker for metabolic syndrome in the general population. This study investigated the association between adiponectin levels and metabolic syndrome in patients treated with atypical antipsychotics.Methods: Anthropometric and metabolic parameters and serum adiponectin levels were assessed in hospitalized patients with schizophrenia who had used the same atypical antipsychotic for at least 3 months. Retrospective reviews of the patients' medical records were conducted to obtain demographic data and pretreatment characteristics.Results: The study included 567 schizophrenia patients treated with clozapme (n = 231 olanzapine (n = 94) and risperidone (n = 242), for an average of 45.8 +/- 27.8 months. The prevalence of metabolic syndrome among all subjects was 23.8%. The clozapine group had a higher prevalence of metabolic syndrome (28.7%) than did the olanzapine (24.2%) and risperidone groups (19.5%) (P=0.039), and the clozapine group had lower levels of adiponectin (8.46 +/- 6.02 mg/mL) than did the olanzapine (10.26 +/- 4.9 mg/mL) and risperidone groups (10.69 +/- 7.43 mg/mL) (P=0.001). Adiponectin level was negatively correlated with body mass index (BMI) increase after initiation of antipsychotic treatment. Cross-sectional regression analysis showed that age (OR,= 1.042, P=0.001), BMI (OR=1.404, P